Despite a push by the Trump administration to slash prices, rare disease drugmakers are trying to avoid price cuts.[5008660] The pharmaceutical industry is under pressure from lawmakers who have been pushing for lower prices on life-saving medications.[4982507] Novartis reported second-quarter earnings and reaffirmed its 2026 guidance, but the company is still facing scrutiny over its pricing practices.[4982507] Agios Pharmaceuticals has discontinued development of a next-generation drug for sickle cell disease after a Phase 2 study failed to show significant benefits.[4982507] The company's decision comes as the industry faces pressure from lawmakers and regulators over high prices for rare diseases drugs.[4982507]